ImmunXperts

We are continually examining our solutions based on market and client dynamics. We are also committed to develop our in-house scientific and operational talent by investing in training and development programs. Drug discovery and development is a complex and time-consuming process that faces numerous challenges despite ongoing innovation. Our growth strategy is a carefully calibrated blend of in-house innovation and strategic acquisitions, aimed at providing our clients with access to the latest scientific capabilities, solutions, and expertise. ImmunXperts, a Q2 Solutions Company, provides trusted immunogenicity risk assessment services, including in silico and in vitro methods, using T-cell activation and proliferation as a surrogate marker for the induction of anti-drug antibodies, cytokine release assays, and MHC-associated peptide proteomics (MAPPS). Our methods provide functional insights into immune-mediated adverse events.ImmunXperts also performs functional screening assays for drug candidates in immuno-oncology, cell and gene therapy and other disease areas. Our ImmunAcademy services provide theoretical immunogenicity and immunology courses, protocol review and optimization, and hands-on training, including training on optimal procedures for the isolation and cryopreservation of PBMCs from whole blood.Located in Gosselies, Belgium, our ImmunXperts team assists clients in advancing programs from discovery to pre-IND and exploratory clinical stages.